Naxiglo (Human Normal Immunoglobulin)

Human normal immunoglobulin, the active ingredient in Naxiglo, is an immunoglobulin presented as a subcutaneous injection for passive immunity replacement. It is used to treat patients with primary or secondary immunodeficiency, immune thrombocytopenic purpura, and chronic inflammatory demyelinating polyneuropathy.

GNH USA supplies Naxiglo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics to ensure product integrity across global markets. Clients benefit from reliable delivery timelines and regulatory support.

Naxiglo is employed in immunoglobulin replacement therapy to restore deficient antibody levels in various immune disorders. - Primary immunodeficiency diseases: restores normal IgG levels, reducing infection frequency. - Secondary immunodeficiency (e.g., chemotherapy or bone marrow transplantation): provides passive immunity to protect against opportunistic infections. - Immune thrombocytopenic purpura: modulates immune response, helping increase platelet counts. - Chronic inflammatory demyelinating polyneuropathy: supplies antibodies that may improve nerve function and reduce disease activity.

Administration of subcutaneous human normal immunoglobulin may be associated with a range of adverse reactions.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Headache: transient headache occurring shortly after infusion. - Fatigue: feeling of tiredness or low energy. - Nausea: mild gastrointestinal upset. - Low-grade fever: temporary rise in body temperature.

Serious or Rare Side Effects: - Thromboembolic events: blood clots that can affect veins or arteries. - Renal impairment: sudden decrease in kidney function. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Hemolysis: destruction of red blood cells leading to anemia. - Aseptic meningitis: inflammation of the meninges without infection.

Prior to prescribing Naxiglo, clinicians should consider several safety precautions to minimize risk. - Assess immunoglobulin levels: confirm deficiency before initiating therapy. - Screen for renal disease: monitor kidney function, especially in patients with pre‑existing impairment. - Evaluate thrombotic risk: avoid use in individuals with recent clotting events. - Monitor for allergic reactions: observe patients during and after the first administration. - Adjust dosage in renal insufficiency: consider reduced volume or slower infusion rates. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Human normal immunoglobulin can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Live vaccines: may reduce vaccine efficacy and increase risk of infection. - High‑dose aspirin or anticoagulants: increase bleeding risk when combined with immunoglobulin infusion.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., cyclophosphamide, azathioprine): may alter immune response, requiring dose adjustments. - Diuretics: potential for renal stress; monitor fluid balance. - ACE inhibitors: watch for increased risk of renal dysfunction. - Monoclonal antibodies targeting B‑cells: possible additive immunomodulation. - Blood pressure medications: observe for hypotensive episodes during infusion.